Trident Texofab Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, sales was INR 475.64 million compared to INR 359.34 million a year ago. Revenue was INR 478.34 million compared to INR 363.09 million a year ago. Net income was INR 10.13 million compared to INR 1.69 million a year ago. Basic earnings per share from continuing operations was INR 1.01 compared to INR 0.17 a year ago. Diluted earnings per share from continuing operations was INR 1.01 compared to INR 0.17 a year ago.